Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > JNJ & Liver Cancer

<< Previous

Bullboard Posts

Next >>

Post by pelabooston Sep 09, 2023 7:21am

288 Views

Post# 35627455

JNJ & Liver Cancer

@ dude on ST

in re your post about hepatitis c and liver cancer.

Many years ago a respected UK group suggested reolysin, now known as pela, SHOULD, not could, be used in Africa to fight liver cancer. That went nowhere. as ONC was likely trying to stay focussed on limited funds just as now.

I am quite certain of the above but I cannot find the article, and I dare say not overly important as time is not on our side.

The time to put up has arrived.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages